Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

McMag-MASSIVE DOT HERE WOW-

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
nidan7500 Member Profile
 
Followed By 42
Posts 8,155
Boards Moderated 0
Alias Born 09/21/16
160x600 placeholder
BTIG Remains a Buy on Anavex Life Sciences (AVXL) TipRanks - 1/19/2022 1:45:28 AM
Anavex Life Sciences (AVXL) Gets a Buy Rating from H.C. Wainwright TipRanks - 1/11/2022 6:45:12 AM
JonesTrading Reaffirms Their Buy Rating on Anavex Life Sciences (AVXL) TipRanks - 1/10/2022 12:55:34 PM
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71 GlobeNewswire Inc. - 1/10/2022 7:00:00 AM
Anavex Life Sciences Promotes Walter E Kaufmann, M.D. to Chief Scientific Officer and Appoints Edward R Hammond, M.D., M.P.H., Ph.D., as Chief Medical Officer GlobeNewswire Inc. - 1/6/2022 7:00:00 AM
Anavex Life Sciences Updates 2 Key Risk Factors TipRanks - 1/6/2022 6:01:37 AM
Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference GlobeNewswire Inc. - 1/5/2022 7:00:00 AM
Dawson James Maintains a Buy Rating on Anavex Life Sciences (AVXL) TipRanks - 1/5/2022 4:10:29 AM
Anavex Life Sciences to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 12/14/2021 7:00:00 AM
Anavex Life Sciences to Present at the 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/29/2021 7:00:00 AM
Anavex Life provides key updates on clinical trials in rare genetic neurological disorders Seeking Alpha - 11/24/2021 9:40:36 AM
Anavex Life Sciences EPS misses by $0.39 Seeking Alpha - 11/24/2021 7:07:01 AM
Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Year End Financial Results GlobeNewswire Inc. - 11/24/2021 7:00:00 AM
Notable earnings after Wednesday's close Seeking Alpha - 11/23/2021 5:35:23 PM
Anavex Life Sciences FY 2021 Earnings Preview Seeking Alpha - 11/23/2021 1:20:23 PM
Notable earnings before Wednesday's open Seeking Alpha - 11/23/2021 10:42:34 AM
Anavex Life Sciences to Announce Fiscal 2021 Year End Financial Results on Wednesday, November 24, 2021 GlobeNewswire Inc. - 11/17/2021 7:00:00 AM
Anavex Life Sciences Announces Participation at Upcoming Lausanne VIII Workshop Panel - Building Global Momentum for Interventions in Alzheimer’s Disease GlobeNewswire Inc. - 11/10/2021 7:00:00 AM
Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference GlobeNewswire Inc. - 10/15/2021 7:00:00 AM
Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease GlobeNewswire Inc. - 10/13/2021 7:00:00 AM
Cassava down after phase 3 simufilam announcement; other Alzheimer's names follow Seeking Alpha - 10/6/2021 12:51:22 PM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/28/2021 8:00:00 AM
Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021 GlobeNewswire Inc. - 9/27/2021 9:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2021 8:11:01 AM
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market® GlobeNewswire Inc. - 9/27/2021 7:00:00 AM
nidan7500   Thursday, 10/29/20 02:29:46 PM
Re: McMagyar post# 279214
Post # of 346643 
McMag
Quote:
-MASSIVE DOT HERE WOW-

I just got this from Alzheimer’s Association

It is curious WHY they would send this letter out..
Harry Johns Signature
Harry Johns
Chief Executive Officer

Are they trying to put pressure on FDA?
Is this for Anavex or Biogen?

This message is sent to all Alzheimer's Association and Alzheimer's Impact Movement board members, all Alzheimer's Association staff, and volunteers and supporters of AIM and the Alzheimer's Association.
I want to be sure you know about an important development that all of your contributions to the Alzheimer’s Association have helped make possible.

As you well know, for decades millions of Americans and their loved ones have waited for a new, more effective treatment for Alzheimer’s disease to be available. On November 6, a Food and Drug Administration (FDA) Advisory Committee is meeting to review clinical trial data for a new drug developed for treating cognitive and functional decline in early Alzheimer’s disease.

Given the devastating toll of this disease and the publicly released research data, the Alzheimer’s Association has submitted a statement supporting approval to the FDA Advisory Committee, which will make its recommendation to the FDA.

Whatever the final decision by the FDA, this is an important moment. We have never before been this close to approval of a drug for Alzheimer’s that could change the progression of the disease, not just the symptoms.

You can rightly be proud of what you’ve done to advance the Alzheimer’s Association’s world leading research program — we have played a critical role in every major advancement in the field. I am personally grateful to you for your relentless dedication to our work toward a world without Alzheimer's and all other dementia.

Without you, none of this happens.

I look forward to sharing more news with you about this as it develops. As always, thank you for everything you do to advance our mission to make a difference today and tomorrow for all of our constituents.

Harry Johns Signature
Harry Johns
Chief Executive Officer



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences